^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mitomycin

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    7d
    Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanxi Province Cancer Hospital
    New P2 trial
    |
    HER-2 expression
    |
    Aidixi (disitamab vedotin) • mitomycin
    8d
    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=21, Recruiting, University of Chicago | Trial completion date: Jun 2026 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Jun 2030
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • mitomycin
    10d
    FOXHIPECT4: Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer (clinicaltrials.gov)
    P3, N=1083, Recruiting, Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitomycin
    11d
    A Hypoxia-Activated Supramolecular Albumin Conjugate for Tumor-Selective Chemotherapy via Host-Guest Recognition and Reductive Drug Release. (PubMed, ACS Appl Mater Interfaces)
    Using mitomycin C (MMC) as a model drug, we show that MAC enables precise hypoxia-triggered intracellular drug release, efficient lysosomal escape, and enhanced mitochondrial dysfunction...In vivo studies further demonstrate that MMC-MAC achieves rapid and sustained tumor accumulation, significantly suppresses tumor growth, induces robust apoptosis, alleviates tumor hypoxia, and exhibits improved systemic biosafety compared with free MMC. This work establishes a supramolecular-biological hybrid strategy that integrates host-guest chemistry, albumin-based delivery, and hypoxia-responsive activation into a single platform, providing a modular and generalizable paradigm for constructing tumor microenvironment-selective nanomedicines with enhanced therapeutic index.
    Journal
    |
    NQO1 (NAD(P)H dehydrogenase, quinone 1)
    |
    mitomycin
    16d
    A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (clinicaltrials.gov)
    P3, N=236, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    gemcitabine • epirubicin • mitomycin • Pinorubin (pirarubicin) • SHR-1501
    17d
    An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing. (PubMed, Br J Cancer)
    3D-UHU-TU model is useful for testing both treatment safety and efficacy on different grades of bladder cancer. Future use of primary tumour spheroids in place of cell lines may allow a personalised medicine approach.
    Preclinical • Journal • IO biomarker
    |
    CASP3 (Caspase 3) • CDH2 (Cadherin 2) • GATA3 (GATA binding protein 3)
    |
    mitomycin
    20d
    IMGeS: The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy (clinicaltrials.gov)
    P2, N=82, Recruiting, National Cancer Center, Korea | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date
    |
    gemcitabine • mitomycin
    27d
    RETAIN BLADDER: Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) (clinicaltrials.gov)
    P2, N=78, Completed, Fox Chase Cancer Center | Active, not recruiting --> Completed | Trial completion date: Feb 2034 --> Dec 2025 | Trial primary completion date: Feb 2027 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • 5-fluorouracil • doxorubicin hydrochloride • mitomycin • vinblastine
    1m
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, University of Nebraska | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial primary completion date
    |
    5-fluorouracil • mitomycin • BMX-001
    1m
    Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Mar 2026 --> Aug 2026
    Trial initiation date
    |
    mitomycin
    1m
    Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, University of Washington
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • Padcev (enfortumab vedotin-ejfv) • mitomycin
    1m
    Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 ) (clinicaltrials.gov)
    P3, N=390, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • Padcev (enfortumab vedotin-ejfv) • mitomycin